Data from Caris Registry clinical outcomes presented at ASCO annual meeting

Caris Life Sciences® and investigators from Inova Fairfax Hospital presented the first clinical outcomes data presentation from the Caris Registry™ at the 50^th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., this weekend. This data, focusing on patients with ovarian cancer, demonstrated significant improvement in survival in women with ovarian cancer.

"We have long hypothesized that personalizing ovarian cancer therapy selection through tumor profiling would benefit patients, and this study is a promising step forward in validating that premise for these patients," said William McGuire, M.D., Inova Fairfax Hospital.

Additionally, this data demonstrates the importance of avoiding inappropriate therapy. "We have found that the underlying biology is also a powerful predictor of therapies that should be avoided for ovarian cancer patients. Patients who receive a cytotoxic agent when their tumor is not likely to respond, experience a significant negative impact on survival," said David Spetzler, Ph.D., Vice President, Research & Development, Caris Life Sciences. "Thus a patient's outcome is strongly influenced by the ability to select appropriate therapies and avoid inappropriate therapies enhanced with the knowledge of the underlying tumor biology provided by Caris Molecular Intelligence™ service."

Based on a 450 patient cohort, this data reported that treatments consistent with the predictions of molecular profiling significantly improved overall survival in patients with ovarian, primary peritoneal and fallopian tube carcinomas. Patients were stratified based on the chemotherapeutic agents administered during the course of their disease. Of the 450 patients, there were 278 that could be grouped into two cohorts, those whose treatments were predicted to be of benefit (170) and those who received at least one treatment predicted to be of lack of benefit (178). There were no significant differences in the baseline characteristics of these two cohorts.

Select highlights from this clinical study include:

• Patients in the Benefit cohort experienced significantly longer post-profiling survival, as evidenced by a 46 percent reduction in the risk of death, compared to the Lack of Benefit cohort (Hazard Ratio = 0.54, 95 percent CI 0.37-0.80; p=0.0018).
• Median overall survival observed for patients included in the Benefit cohort (158.0 months) compared to patients included in the Lack of Benefit cohort (63.4 months).
•  Patients in the Benefit cohort also trended toward significantly longer overall survival, as evidenced by a 31 percent reduction in the risk of death, compared to the Lack of Benefit cohort (Hazard Ratio = 0.69, 95 percent CI 0.47-1.02; p=0.065).

This entire poster may be viewed at: http://www.carislifesciences.com/media/pdf/The-impact-of-tumor-molecular-profile-directed-treatment-on-survival-in-ovarian-cancer_ASCO2014-oliver-mcguire-spetzler.pdf.

"Oncologists dealing with particularly complex cancers should realize the value that molecular profiling with Caris Molecular Intelligence can play in helping their patients battle this disease as demonstrated by these data," said Caris Life Sciences Chief Medical Officer, Sandeep K. Reddy, M.D.

Caris Life Sciences presented an extraordinary amount of data at ASCO through oral presentation, poster highlights, and posters. The entire set of submissions may be viewed at: http://www.carislifesciences.com/asco-2014/.